Docetaxel Concept

subject area of

• A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer  Journal Articles
• A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer  Journal Articles
• A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium  Journal Articles
• A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia  Journal Articles
• A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a  Conferences
• A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer  Journal Articles
• A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy  Journal Articles
• A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients  Journal Articles
• Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy  Journal Articles
• Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621  Journal Articles
• Amplification of MUC1 in prostate cancer metastasis and CRPC development  Journal Articles
• Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)  Journal Articles
• Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel  Journal Articles
• Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer  Journal Articles
• Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials  Journal Articles
• Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy  Journal Articles
• Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients  Journal Articles
• Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy  Journal Articles
• Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis  Journal Articles
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Journal Articles
• Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China  Journal Articles
• Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial  Journal Articles
• Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial  Journal Articles
• Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry  Journal Articles
• Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study  Journal Articles
• Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes  Journal Articles
• Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies  Journal Articles
• Effect of docetaxel (taxotere) on expression of radiation-induced lethal mutations in human cell lines  Journal Articles
• Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials  Journal Articles
• Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial  Journal Articles
• European oncologists' preferences for the management of breast cancer: case presentations and expert commentary  Journal Articles
• Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer  Journal Articles
• Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic  Journal Articles
• Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer  Journal Articles
• Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy  Journal Articles
• Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design  Journal Articles
• Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect  Journal Articles
• Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer  Journal Articles
• Malignant pleural mesothelioma: a phase II trial with docetaxel  Journal Articles
• Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?  Journal Articles
• Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer  Journal Articles
• New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities  Journal Articles
• Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin  Journal Articles
• Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline  Journal Articles
• Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx  Journal Articles
• Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome  Journal Articles
• Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial  Journal Articles
• Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity  Journal Articles
• Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer  Journal Articles
• Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy  Journal Articles
• Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition  Journal Articles
• Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer  Journal Articles
• Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer  Journal Articles
• Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer  Journal Articles
• Radiosensitization of Colon Cancer Cell Lines by Docetaxel: Mechanisms of Action  Journal Articles
• Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer  Conferences
• Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c  Journal Articles
• Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada  Journal Articles
• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer  Journal Articles
• Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America  Journal Articles
• Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  Journal Articles
• Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer  Journal Articles
• Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy  Journal Articles
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma  Journal Articles
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.  Journal Articles
• Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa  Journal Articles
• Symptom clusters using the Brief Pain Inventory in patients with breast cancer  Journal Articles
• Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline  Journal Articles
• Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review  Journal Articles
• Targeting prostate cancer with HTI‐286, a synthetic analog of the marine sponge product hemiasterlin  Journal Articles
• Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline  Journal Articles
• Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial  Journal Articles
• The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis  Journal Articles
• The Role of Serotonin in Breast Cancer Stem Cells  Journal Articles
• The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Journal Articles
• The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.  Journal Articles
• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline  Journal Articles
• Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial  Journal Articles
• Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials  Journal Articles
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study  Journal Articles
• Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421  Journal Articles